Hytest is excited to announce the launch of its new HIV p24 monoclonal antibodies (MAbs) under Cat. # 3H24. All 7 MAbs--GA12, GA17, GA32, GA34, GA38, GA39, and GA54-- are designed to be used for the development of next-generation HIV p24 antigen immunoassays.  

Sensitivity analysis on the CLIA platform using the WHO HIV-1 p24 International Standard (NIBSC code: 90/636) indicates that the recommended pairs achieve an analytical sensitivity of 0.5–0.64 IU/mL, exceeding the requirements set by the EU IVDR Class D regulations. Meanwhile, the specificity of the recommended pairs when testing clinical samples reaches over 99.95%.  

We also ensure that our antibody pairs recognize a broad range of HIV-1 subtypes (A1, B, C, D, F1/CRF12_BF/BFrec, G, CRF20_BG, CRF01_AE, CRF02_AG, H, and Group O) as well as the HIV-2 p26 antigen, enabling reliable detection across diverse HIV variants.  

This launch is part of Hytest’s ongoing commitment to expanding its infectious disease portfolio to better serve our customers and support the development of cutting-edge diagnostic solutions.  

More information: